Regular ArticleAbsence of MPTP-Induced Neuronal Death in Mice Lacking the Dopamine Transporter☆
References (39)
- et al.
Co-expression of dopamine transporter mRNA and tyrosine hydroxylase mRNA in ventral mesencephalic neurones
Mol. Brain Res.
(1993) - et al.
Effect of different schedules of MPTP administration on dopaminergic neurodegeneration in mice
Exp. Neurol.
(1997) - et al.
A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey
Brain Res.
(1997) - et al.
Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter
Neuron
(1997) - et al.
Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain
Mol. Brain Res.
(1993) - et al.
MPTP and MPP+ cause rapid ATP depletion in isolated hepatocytes
Biochem. Biophys. Res. Commun.
(1986) - et al.
Increase efflux rather than oxidation is the mechanism of glutathione depletion by MPTP
Biochem. Biophys. Res. Commun.
(1987) - et al.
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
Eur. J. Pharmacol.
(1991) - et al.
The neurotoxin MPTP causes degeneration of specific nucleus A8, A9, and A10 dopaminergic neurons in the mouse
Neurodegeneration
(1996) - et al.
The selective accumulation of MPP+ in the substantia nigra: A key to neurotoxicity
Life Sci.
(1985)
Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Neurodegeneration
MPTP and free radicals in vitro
Biochem. Pharmacol.
Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism
Neurosci. Lett.
Dopamine transporter mRNA: Dense expression in ventral midbrain neurons
Mol. Brain Res.
The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice
Eur. J. Pharmacol.
Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age
Proc. Natl. Acad. Sci. USA
MPTP-induced hemiparkinsonism in monkeys: Behavioral, mechanographic, electromyographic and immunohistochemical studies
Exp. Brain Res.
Kinetics of nigral degeneration in a chronic model of MPTP-treated mice
Neurosci. Lett.
Chimeric dopamine–norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium
Proc. Natl. Acad. Sci. USA
Cited by (185)
Animal models of developmental dyslexia: Where we are and what we are missing
2021, Neuroscience and Biobehavioral ReviewsHeterogeneity of dopamine release sites in health and degeneration
2020, Neurobiology of DiseaseMitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models
2019, Journal of Biological ChemistryCitation Excerpt :Although in agreement with studies from other groups (29–33), the microsomal CYP2D6 supported by cytochrome P450 reductase (CYPOR) catalyzed the demethylation of MPTP to nontoxic metabolites. Our results showing the ability of Mt2D6 to metabolize MPTP to the cationic form MPP+ are a paradigm shift because it is widely believed that monoamine oxidase B, present on the mitochondrial outer membrane of glial cells, carries out oxidation of MPTP, and the metabolites are then transported to dopaminergic neurons through dopamine transporters (28, 34–37). Both monoamine oxidase B and dopamine transporters have been targets of drug development for PD over the past two to three decades.
Chemosensory dysfunction in neurodegenerative diseases
2019, Handbook of Clinical Neurology
- ☆
Abbreviations used: DAT, dopamine transporter; DAT+/+, wild type; DAT+/−, heterozygote; DAT−/−, homozygote; TH-IR, tyrosine hydroxylase immunoreactivity; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP+, 1-methyl-4-phenylpyridinium; PD, Parkinson's disease; SNc, substantia nigra pars compacta.
- 1
To whom correspondence should be addressed. Fax: 33 5 56 98 61 82. E-mail:[email protected].